[-] Show simple item record

dc.contributor.authorSlatkoff, Susaneng
dc.contributor.authorGamboa, Stepheneng
dc.contributor.authorZolotor, Adam J.eng
dc.contributor.authorMounsey, Anne L.eng
dc.contributor.authorJones, Kohareng
dc.contributor.otherFamily Physicians Inquiries Networkeng
dc.date.issued2011eng
dc.description.abstractDo not routinely screen all men over the age of 50 for prostate cancer with the prostate-specific antigen (PSA) test. Consider screening men younger than 75 with no cardiovascular or cancer risk factors -- the only patient population for whom PSA testing appears to provide even a small benefit. Stength of recommendation: B: Based on a meta-analysis of 6 randomized controlled trials (RCTs) with methodological limitations, and a post hoc analysis of a large RCT.eng
dc.identifier.urihttp://hdl.handle.net/10355/10961
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionPriority Updates to Research Literature (PURLs) (2011)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 60, no. 06 (June 2011): 357-360.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subject.lcshProstate -- Cancer -- Diagnosiseng
dc.subject.lcshProstate-specific antigeneng
dc.subject.otherProstate cancereng
dc.subject.otherCancer screeningeng
dc.titlePSA testing: When it's useful, when it's noteng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record